Literature DB >> 28054172

The occurrence of lateral shift in cervical dystonia.

Marcello Esposito1, Silvio Peluso2, Raffaele Dubbioso2, Roberto Allocca2, Filippo Iorillo2, Antonietta Coppola2, Lucio Santoro2.   

Abstract

Aim of this study is to identify factors contributing the occurrence of neck lateral shift (LS) in patients with cervical dystonia (CD). A retrospective analysis focused on the treatment with botulinum toxin (BTX) was conducted on 38 consecutive idiopathic CD patients comparing subjects with and without LS. The main result was the evidence of a significantly higher BTX inter-side dose difference in patients with LS suggesting that this uncommon phenotype may be an artifact of chronic therapy with BTX.

Entities:  

Keywords:  Botulinum toxin; Cervical dystonia; Lateral shift

Mesh：

Substances：

Year:  2017        PMID： 28054172     DOI： 10.1007/s10072-016-2799-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  12 in total

1.  Spontaneously changing muscular activation pattern in patients with cervical dystonia.

Authors:  A Münchau; S R Filipovic; A Oester-Barkey; N P Quinn; J C Rothwell; K P Bhatia
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

2.  Predictive factors of outcome in primary cervical dystonia following pallidal deep brain stimulation.

Authors:  Jennifer L Witt; Elena Moro; Rima S Ash; Clement Hamani; Philip A Starr; Andres M Lozano; Mojgan Hodaie; Yu-Yan Poon; Leslie C Markun; Jill L Ostrem
Journal:  Mov Disord       Date:  2013-06-20       Impact factor: 10.338

3.  Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.

Authors:  Daniel Truong; Matthew Brodsky; Mark Lew; Allison Brashear; Joseph Jankovic; Eric Molho; Olga Orlova; Sofia Timerbaeva
Journal:  Parkinsonism Relat Disord       Date:  2010-03-31       Impact factor: 4.891

Review 4.  Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.

Authors:  Jack J Chen; Khashayar Dashtipour
Journal:  Pharmacotherapy       Date:  2013-02-11       Impact factor: 4.705

Review 5.  Phenomenology and classification of dystonia: a consensus update.

Authors:  Alberto Albanese; Kailash Bhatia; Susan B Bressman; Mahlon R Delong; Stanley Fahn; Victor S C Fung; Mark Hallett; Joseph Jankovic; Hyder A Jinnah; Christine Klein; Anthony E Lang; Jonathan W Mink; Jan K Teller
Journal:  Mov Disord       Date:  2013-05-06       Impact factor: 10.338

6.  Double-blind study of botulinum toxin in spasmodic torticollis.

Authors:  J K Tsui; A Eisen; A J Stoessl; S Calne; D B Calne
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

7.  Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle.

Authors:  Joanna M Flowers; Lucy A Hicklin; Marie-Helene Marion
Journal:  Mov Disord       Date:  2011-09-12       Impact factor: 10.338

Review 8.  Orthopedic and neurological complications of cervical dystonia--review of the literature.

Authors:  C Konrad; J Vollmer-Haase; K Anneken; S Knecht
Journal:  Acta Neurol Scand       Date:  2004-06       Impact factor: 3.209

9.  [The phenomenology of cervical dystonia].

Authors:  G Reichel; A Stenner; A Jahn
Journal:  Fortschr Neurol Psychiatr       Date:  2009-05-05       Impact factor: 0.752

10.  The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.

Authors:  Marcello Esposito; A Fasano; C Crisci; R Dubbioso; R Iodice; Lucio Santoro
Journal:  Neurol Sci       Date:  2013-08-15       Impact factor: 3.307
View more
  1 in total

1.  Management of Anterocapitis and Anterocollis: A Novel Ultrasound Guided Approach Combined with Electromyography for Botulinum Toxin Injection of Longus Colli and Longus Capitis.

Authors:  Michael Farrell; Barbara I Karp; Panagiotis Kassavetis; William Berrigan; Simge Yonter; Debra Ehrlich; Katharine E Alter
Journal:  Toxins (Basel)       Date:  2020-09-30       Impact factor: 4.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.